<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00199082</url>
  </required_header>
  <id_info>
    <org_study_id>GMALL05</org_study_id>
    <nct_id>NCT00199082</nct_id>
  </id_info>
  <brief_title>Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults</brief_title>
  <official_title>Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicola Goekbuget</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the efficacy and tolerability of alternating short cycles of high-dose
      and conventional chemotherapy in combination with rituximab in CD20 positive patients,
      followed by local radiation therapy in the case of initial mediastinal or central nervous
      system (CNS) involvement or a residual tumor after chemotherapy. A dose-reduced regimen is
      offered for patients estimated to be over 55 years, biologically.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission duration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose and time compliance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to National Cancer Institute (NCI)-Common Toxicity Criteria (CTC)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death under therapy and in complete remission (CR)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Localisations of relapse</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Burkitt's Lymphoma</condition>
  <condition>Burkitt's Leukemia</condition>
  <condition>Mediastinal Neoplasms</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <condition>Large Cell Anaplastic Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone/Prednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP16</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine/Vindesine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Irradiation (in specific conditions)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Burkitt's leukemia or Burkitt's lymphoma or primary mediastinal large B-cell lymphoma
             or B-precursor lymphoblastic lymphoma or large cell anaplastic lymphoma

          -  Age &gt; 15 years

          -  Written informed consent

        Exclusion Criteria:

          -  Serious secondary diseases, including psychiatric conditions, under which the required
             therapy compliance is not to be expected

          -  HIV infection

          -  Secondary lymphoma following prior chemotherapy/radiotherapy or active second
             malignancy

          -  Known severe allergy to foreign proteins

          -  Pre-treatment other than 1 cycle CHOP or similar; &lt; 1 week of another chemotherapy.

          -  Pregnancy or nursing

          -  Participation in other studies that interfere with study therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola Goekbuget, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Frankfurt (Main)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Medical Dept. II</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.leukemia-trials.eu</url>
    <description>European Leukemia Trial Registry</description>
  </link>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>August 4, 2016</last_update_submitted>
  <last_update_submitted_qc>August 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Nicola Goekbuget</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>High-grade NHL</keyword>
  <keyword>De novo</keyword>
  <keyword>Mature B-ALL</keyword>
  <keyword>Burkitt'S NHL</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Primary mediastinal diffuse large cell lymphoma</keyword>
  <keyword>B-precursor lymphoblastic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Mediastinal Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Vindesine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

